NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer
Status:
Recruiting
Trial end date:
2023-10-31
Target enrollment:
Participant gender:
Summary
The purpose of this Phase I study is to determine the recommended phase 2 dose (RP2D) and
safety profile of NBTXR3 activated by radiation therapy with concurrent chemotherapy for the
treatment of patients with esophageal adenocarcinoma. NBTXR3 is a drug that when activated by
radiation therapy, may cause targeted destruction of cancer cells. Radiation therapy uses
high energy x-rays to kill tumor cells and shrink tumors. Chemotherapy drugs, such as
oxaliplatin, fluorouracil, capecitabine, docetaxel, paclitaxel, and carboplatin, work in
different ways to stop the growth of tumor cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. Giving NBTXR3 activated by radiation
therapy with concurrent chemotherapy may help control the disease.